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Serine/arginine-rich (SR) proteins are essential splicing factors with one or two RNA-recognition motifs (RRMs) and a C-terminal
arginine- and serine-rich (RS) domain. SR proteins bind to exonic splicing enhancers via their RRM(s), and from this position are
thought to promote splicing by antagonizing splicing silencers, recruiting other components of the splicing machinery through
RS-RS domain interactions, and/or promoting RNA base-pairing through their RS domains. An RS domain tethered at an exonic
splicing enhancer can function as a splicing activator, and RS domains play prominent roles in current models of SR protein
functions. However, we previously reported that the RS domain of the SR protein SF2/ASF is dispensable for in vitro splicing of
some pre-mRNAs. We have now extended these findings via the identification of a short inhibitory domain at the SF2/ASF N-
terminus; deletion of this segment permits splicing in the absence of this SR protein’s RS domain of an IgM pre-mRNA
substrate previously classified as RS-domain-dependent. Deletion of the N-terminal inhibitory domain increases the splicing
activity of SF2/ASF lacking its RS domain, and enhances its ability to bind pre-mRNA. Splicing of the IgM pre-mRNA in S100
complementation with SF2/ASF lacking its RS domain still requires an exonic splicing enhancer, suggesting that an SR protein
RS domain is not always required for ESE-dependent splicing activation. Our data provide additional evidence that the SF2/ASF
RS domain is not strictly required for constitutive splicing in vitro, contrary to prevailing models for how the domains of SR
proteins function to promote splicing.
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INTRODUCTION
The SR proteins are a family of conserved splicing factors that
consist of either one or two N-terminal RNA recognition motifs
(RRM) and a C-terminal arginine- and serine-rich (RS) domain
[1,2]. SR proteins promote constitutive and alternative splicing
through multiple modes [3], some of which are presumed to
require their RS domains. Exonic splicing enhancers (ESEs) are
degenerate 6–8 nucleotide motifs that promote exon inclusion, in
many cases through the action of SR proteins [4–9]. SR proteins
bind to ESEs via their RRM(s) [10], whereas their RS domains are
thought to function as protein-protein interaction modules that
facilitate exon inclusion by recruiting components of the basal
splicing machinery to the flanking 59 and 39 splice sites early in
splice-site recognition [11]. In yeast two-hybrid and Far Western
assays, the SR protein SF2/ASF was shown to interact with itself
and with the U1-snRNP-specific protein U1-70K and the small
subunit of the U2AF heterodimer, U2AF
35; these protein-protein
interactions required the RS domains of each protein [12,13].
Subsequently it was proposed that SR proteins can promote
recruitment of the U1 snRNP to the 59 splice site through SR
protein RS-domain-mediated interactions with U1-70K [14].
However, the RS domain of SF2/ASF alone is unable to interact
with U1-70K in vitro [15]. Enhancer-bound SR proteins are also
thought to escort U2AF
65 to the 39 splice site polypyrimidine tract
through RS-domain-mediated recruitment of U2AF
35 [16,17,18].
A role for SR proteins in bringing U2AF
65 to the polypyrimidine
tract is supported by several experiments in which improving this
tract can relieve the requirement for an ESE for pre-mRNAs with
enhancer-dependent introns [19,20,21]. However, other experi-
ments failed to detect changes in U2AF recruitment in the
presence versus in the absence of an ESE [22,23], calling into
question the hypothesis that an ESE-bound RS domain is required
for recruitment of U2AF
65. Although the aforementioned func-
tions of SR proteins are assumed to occur via RS-domain-
mediated protein-protein interactions, it has not yet been
demonstrated that such interactions occur in the context of
a functional spliceosome [24].
A second mode by which SR proteins promote exon inclusion is
by antagonizing the negative regulation conferred by exonic
splicing silencers (ESSs), pre-mRNA regulatory elements that
inhibit exon inclusion in both constitutive and alternative splicing
[25]. Although the mechanisms by which SR proteins counteract
the effects of splicing silencers are not well understood [4], their
RS domains are not always required for this function, as SF2/ASF
lacking its RS domain can act from the position of an HIV tat exon
3 ESE to antagonize an ESS present in the same exon [26].
A third mechanism by which SR proteins have been reported to
promote splicing is by engaging in transient RS domain-pre-
mRNA contacts during the course of splicing. An ESE-bound RS
domain can interact directly with the branchpoint of an IgM
substrate in the pre-spliceosomal A complex [27]. The RS
domains of SR proteins bound to ESEs can also act as protein-
RNA interaction modules to promote base-pairing of pre-mRNA
and U5 and U6 snRNAs during the course of pre-mRNA splicing
[28]. However, although it is clear that an RS domain recruited to
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domain tethered to the position of the ESE is not always required,
as splicing of the ESE-dependent substrate dsx lacking its ESE can
also be accomplished simply by the addition of an excess of free
RS domain to nuclear extract [27], consistent with the hypothesis
that the function of an SR protein may be merely to recruit any
RS domain to the vicinity of the splicing signal. On the other
hand, adding an RS domain peptide to nuclear extract is
insufficient to promote exon inclusion for BRCA1 pre-mRNA
exon 18 lacking a functional ESE, whereas recruitment of
a synthetic RS domain to the mutated ESE rescues inclusion of
this exon [29].
The RS domains of SR proteins are conserved, and the serine
residues within these domains are targets of phosphorylation by
multiple kinases, including SRPK1 [30] and SRPK2 [31], Clk/Sty
[32], and DNA topoisomerase I [33]. Phosphorylation of RS
domains influences the subcellular localization of SR proteins
[32,34,35,36]. The phosphorylation state of the RS domain has
a significant influence on SR protein function, as both hyper- and
hypophosphorylated SR proteins are unable to support splicing
[37,38,39]. SR protein RS domains were at one time thought to be
indispensable for constitutive splicing in vitro, yet dispensable for
concentration-dependent effects on alternative splice-site selection
[40,41]. However, we subsequently found that the RS domain of
SF2/ASF is not required for constitutive splicing of several pre-
mRNAs in vitro, including tat23, an ESE-dependent pre-mRNA
known to be regulated by an ESS [42]. Thus, pre-mRNAs could be
classified as either RS-domain-dependent or RS-domain-indepen-
dent, based on their ability to be spliced with an SR protein lacking
its RS domain (‘‘DRS’’). RS-domain-dependence was found to be
related to the strength of the 39 splice site and the requirement for
U2AF
35 [42]. IgM M1-M2 was identified as an RS-domain-
dependent pre-mRNA, congruent with at least some previous
reports that it is U2AF
35-dependent and possesses relatively weak
polypyrimidine-tract and branchpoint sequences [43,44].
IgM M1-M2 has been used by several laboratories as a model
substrate to explore the role(s) of ESEs in promoting pre-mRNA
splicing. However, the functions of the ESE-bound SR protein in
the context of the RS-domain-dependent IgM M1-M2 pre-mRNA
have been controversial, and there are several competing models
for the mechanism by which SF2/ASF promotes splicing at the
ESE position in this substrate. In the recruitment model, SF2/ASF
binds via its RS domain to U2AF
35 to indirectly recruit U2AF
65 to
the polypyrimidine tract [21], whereas in the antagonism model,
the sole function of enhancer-bound SF2/ASF is to prevent PTB
from binding to a downstream ESS [45]. Some experiments with
the IgM M1-M2 substrate strongly support the model for SR
protein function in which an ESE-bound RS domain recruits
U2AF
35 and U2AF
65 to the polypyrimidine tract [21]. However,
other experiments detected no difference in U2AF
35 occupancy on
IgM M1-M2 in the presence and absence of the ESE [23].
The discovery that many but not all substrates could be spliced
with SF2/ASF lacking its RS domain [42] suggested that SR
protein functions might be subdivided into RS-domain-dependent
and RS-domain-independent categories. We prepared various
fragments of SF2/ASF for structural and functional studies,
including versions lacking the C-terminal RS domain and/or an
N-terminal extension that precedes RRM1. N-terminal and C-
terminal extensions of RRMs have been demonstrated to regulate
nucleic acid binding in other splicing factors [46], and we noted
that SF2/ASF and some other SR proteins have N-terminal RRM
extensions. We had previously characterized an N-terminally His-
tagged SF2/ASF lacking the RS domain as unable to complement
S100 for constitutive splicing [40], but omitting this N-terminal tag
allowed the same protein to support splicing of some pre-mRNAs
[42]. These precedents suggested that the natural N-terminus of
SF2/ASF may influence its activity, and we therefore investigated
whether the N-terminal extension preceding RRM1 had any
influence on the splicing activity of DRS with the RS-domain-
dependent substrate IgM M1-M2. Deletion of the N-terminus
from DRS revealed that the RS domain is not required for splicing
of IgM M1-M2, lending further support to our previous finding
that the RS domain of SF2/ASF is sometimes dispensable for
splicing in vitro, and calling for a reevaluation of traditional models
of SR protein function.
RESULTS
The RS domain of SF2/ASF is not required for
splicing of IgM M1-M2 in vitro
To determine whether the splicing activity of the DRS protein is
affected by the N-terminal extension to RRM1, we tested proteins
with mutations and deletions of the N-terminus in an in vitro
splicing assay (Figure 1). IgM M1-M2 was previously characterized
as an RS-domain-dependent substrate, although a low level of
splicing can be detected in S100 complementation assays with our
DRS protein (Figure 1C, lane 4), which consists of amino acids 1-
196 of SF2/ASF. Deletion of the first 11 amino acids of DRS to
produce the DNDRS protein comprising amino acids 12-196
permitted splicing of IgM M1-M2 at a level comparable to that
seen with full-length SF2/ASF (Figure 1C, lanes 2 and 5). Deletion
of the N-terminus from SF2/ASF to produce the DNSF2/ASF
protein also slightly increased the amount of splicing supported by
the protein (Figure 1C, lanes 2 and 3).
Mutational analysis of the N-terminus of SF2/ASF
reveals that conserved amino acids contribute to
the inhibitory effect of the RRM1 extension on
splicing
We observed that deletion of the 11 N-terminal amino acids
(MSGGGVIRGPA) from SF2/ASF and DRS increased the
amount of splicing that could be supported by these proteins,
suggesting that the N-terminus has an inhibitory function. To
identify amino acids within this N-terminal region that may
contribute to inhibition of splicing, we generated SF2/ASF and
DRS proteins with mutations in the N-terminus (Figure 1). Amino
acids 5-10 (GVIRGP) are predicted to have b-strand propensity
(GOR4, Biology Workbench, San Diego Supercomputer Center,
University of California at San Diego; Subramaniam, 1998), and
several other proteins identified through a Basic Local Alignment
Search Tool search (BLAST, National Center for Biotechnology
Information) as having similar motifs to GVIRGP are known to
adopt a b-strand conformation with their homologous residues.
We made both SF2/ASF and DRS proteins with the following
mutations at the N-terminus: deletion of amino acids 5–10 (the
predicted b-strand), a triple mutant of amino acids 6–8 called
V6A/I7A/R8A, and single mutants designated V6A, I7A, R8A,
P10A, and R8E (Figures 1A and 1B). The SF2/ASF and DRS N-
terminus mutant proteins were tested in the in vitro splicing assay
with IgM M1-M2 (Figure 1C) to determine whether mutation of
any of these amino acids relieves the inhibitory effect of the N-
terminus. Most of the N-terminal mutations had little or no effect
on the amount of splicing of IgM M1-M2 in the context of full-
length SF2/ASF (Figure 1C, lanes 6-12). However, of the DRS N-
terminus mutant proteins, DRS: D5-10 and DRS:R8E showed
a significant increase in splicing, relative to their parental protein
DRS (Figure 1C, lanes 13 and 19), with levels of splicing similar to
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with these mutant proteins, relative to DRS, suggests that residues
within amino acids 5-10 contribute to the inhibitory effect of the
N-terminus on splicing, and in particular, that R8 plays a role in
this inhibition.
We carried out a phylogenetic analysis to examine the
conservation of the N-terminal extension of SF2/ASF (Figure 2).
The N-terminal peptide is highly conserved in vertebrate SF2/
ASF orthologs, but not in other SR protein paralogs. Invertebrate
and plant SF2/ASF and a subset of other SR proteins also have N-
terminal extensions, which in most cases include at least one
arginine residue.
The N-terminal extension of RRM1 influences the
ability of SF2/ASF to bind RNA
Protein segments N-terminal or C-terminal to the core RRM
module have been demonstrated to play roles in nucleic acid
recognition for several splicing factors, including U1-70K [47],
U1A [48,49,50], PTB [51], hnRNP C [52], and hnRNP A1 [53],
as well as other RNA-binding proteins with RRMs, such as La
[54] and CstF-64 [55]. As RRM extensions modulate the
specificity of RNA binding, the binding affinity, and/or the
accessibility of the RNA-binding surface for other nucleic acid-
binding proteins, we hypothesized that the SF2/ASF N-terminal
Figure 1. Identification of N-terminal residues of SF2/ASF that contribute to the inhibitory function of this domain. (A) Amino acid sequence of
the N-terminal extension of RRM1 of SF2/ASF, indicating mutations generated and tested by in vitro splicing and UV crosslinking assays. The first
residues of RRM1 are in bold, with the RNP-2 submotif underlined. (B) Recombinant SF2/ASF and mutant proteins used in this study, analyzed by
SDS-PAGE and Coomassie-blue staining. M: molecular-weight markers. (C) In vitro splicing of IgM M1-M2 pre-mRNA in HeLa S100 extract alone (lane
1), and in S100 complemented with 16 pmol of SF2/ASF, DRS, and N-terminus mutant proteins, as indicated (lanes 2-19). The splicing efficiency is
indicated below each lane.
doi:10.1371/journal.pone.0000854.g001
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substrates. The binding of purified recombinant SF2/ASF,
DNSF2/ASF, DRS, DNDRS, DRS: D5-10, and DRS:R8E to
IgM M1-M2 pre-mRNA was assayed by UV crosslinking
(Figure 3). Although there was little difference between the extent
of RNA crosslinking observed for the SF2/ASF and DNSF2/ASF
proteins (Figure 3B, lanes 2 and 3), deletion of the N-terminal
extension in the context of the DRS protein greatly increased the
crosslinking to the IgM M1-M2 RNA (lanes 4 and 5). In addition,
the DRS: D5-10 protein, which exhibited increased splicing
activity relative to its parental DRS protein (Figure 1C, lane 13),
was also more efficiently crosslinked to IgM M1-M2 RNA
Figure 2. Phylogenetic alignment of the N-termini of SF2/ASF orthologs and paralogs. SR protein N-terminal RRM extensions were aligned using
ClustalW. Accession numbers are provided for each sequence in the alignment. Sequences in the b1 strand and arginine residues in the extensions
are indicated by bold lettering.
doi:10.1371/journal.pone.0000854.g002
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the N-terminus of the DRS protein on splicing of IgM M1-M2
may be due to a negative influence of this segment on the protein’s
ability to bind RNA.
The increase in splicing observed with DRS harboring the R8E
mutation (Figure 1C, lane 19) was not strictly correlated with
improvement in RNA binding as measured by UV crosslinking
with purified recombinant proteins, as apparent binding of DRS:
R8E protein to IgM M1-M2 RNA was not greatly increased
relative to binding of DRS (Figure 3B, lanes 4 and 7). Increased
apparent RNA binding in the UV crosslinking assay for DNDRS
and DRS: D5-10 proteins may be a consequence of removal of
a portion of the inhibitory N-terminus, whereas the R8E mutation
may not increase RNA binding to the same extent in this assay
because it preserves the length of the inhibitory N-terminal
extension to RRM1. On the other hand, the UV crosslinking assay
with RNA and purified recombinant proteins does not necessarily
address whether the R8E mutation affects the ability of the DRS
protein to be recruited to IgM M1-M2 pre-mRNA under splicing
conditions.
Splicing of IgM M1-M2 with DNDRS requires the
exonic splicing enhancer
Despite the fact that IgM M1-M2 was previously characterized as
an RS-domain-dependent substrate, and although its splicing can
be activated by an RS domain tethered to the position of its ESE
[21,56,57], we have established through deletion of the N-
terminus from DRS that the RS domain of SF2/ASF is not
required for IgM M1-M2 splicing. We and others have observed
that IgM M1-M2 is an ESE-dependent substrate [7,23,58,59,60].
As several existing models for SR protein function in the IgM M1-
M2 context require an enhancer-bound SR protein or RS domain,
we wished to determine whether the DNDRS protein exerted its
effects through the ESE. Therefore, we deleted the enhancer
region (GAAGGACAGCAGAGACCAAGA, as reported in [23])
from IgM M1-M2 to produce the IgMDE substrate, and tested its
ability to be spliced with the DNDRS protein. We also mutated
other sequences already demonstrated to have a relationship to SR
protein function within the IgM M1-M2 pre-mRNA context, i.e.,
the polypyrimidine tract and the exonic splicing silencer, to test
whether there was any difference in splicing with changes in these
elements, in the presence or absence of the SF2/ASF RS domain.
As already seen in the above experiment (Figure 1C), DNDRS
complemented S100 for splicing of IgM M1-M2 almost as
efficiently as SF2/ASF (Figure 4, lanes 2 and 3). As expected,
IgMDE could not be spliced in S100 complementation with SF2/
ASF, because IgM M1-M2 is an ESE-dependent pre-mRNA
(Figure 4, lane 5). Likewise, DNDRS could not splice IgMDE,
demonstrating that it also activates splicing in an ESE-dependent
manner (Figure 4, lane 6).
The IgM M1-M2 ESS was originally identified in functional
assays by progressive deletion of exonic sequences from the 39 end
of the pre-mRNA, and mapped to the last half of the M2 exon
[58]. The silencer was subsequently more precisely mapped to an
11-nucleotide motif denoted PTB site I (UCUUACGUCUU), and
its cognate repressor protein was identified as pyrimidine tract
binding protein (PTB) [45]. Using an IgM M1-M2 derivative
substrate in which the ESE had been replaced by an MS2
bacteriophage coat protein binding site [61], Shen et al showed in
S100 complementation assays with SF2/ASF that immuno-
depletion of PTB permitted splicing of IgM in the absence of an
MS2-RS protein targeted to the ESE position [45], suggesting that
the primary function of an SR protein bound at this ESE is to
counteract the juxtaposed ESS. To determine whether the RS
domain of an ESE-bound SR protein plays a role in antagonizing
the function of the IgM M1-M2 ESS, we tested an IgM substrate
with a mutant PTB site I (ACAUACGACAU, as in [45]),
IgMPTB, and the PTB mutant substrate also lacking the ESE,
IgMDEPTB, in S100 complementation with SF2/ASF and
DNDRS. More efficient splicing of IgMPTB was observed with
DNDRS than with SF2/ASF (Figure 4, lanes 14 and 15),
suggesting that the RS domain of SF2/ASF is not required for
counteracting the function of the PTB site I silencing element.
However, contrary to the previous report that the PTB site I
mutation can relieve the requirement for the ESE [45], we did not
observe splicing of IgMDEPTB with either SF2/ASF or DNDRS
in our S100 complementation assays (Figure 4, lanes 17 and 18).
The discrepancies between our results and the previously reported
data may be attributable to differences in the methods by which
we tested the substrates; in their S100 complementation assays,
Shen et al immunodepleted PTB from S100, rather than mutating
the PTB site I. It is possible that mutation of the PTB site I might
be insufficient to permit splicing in S100 complementation, for
example, in a scenario in which PTB binds to additional sites in
Figure 3. DRS N-terminus mutations that improve splicing also
increase the ability of DRS to bind IgM M1-M2. (A) Recombinant SF2/
ASF and mutant proteins employed in the crosslinking assay. M:
molecular-weight markers. (B) UV crosslinking of SF2/ASF and variant
proteins to radiolabeled IgM M1-M2 RNA. BSA (lane 1), or purified
recombinant SR proteins SF2/ASF (lane 2), DNSF2/ASF (lane 3), DRS
(lane 4), DNDRS (lane 5), DRS: D5-10 (lane 6), and DRS:R8E (lane 7) were
incubated with uncapped IgM M1-M2 RNA prior to crosslinking, RNAse
digestion, and separation of crosslinked adducts by SDS-PAGE.
doi:10.1371/journal.pone.0000854.g003
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our results are in agreement with other reports that an ESE is
required for splicing of IgM, even in the absence of the ESS
[21,58].
We have demonstrated that DNDRS, like SF2/ASF, activates
splicing in an ESE-dependent manner. As improvement of the
polypyrimidine tract relieves the requirement for an enhancer
when the ESS is not present [21], we attempted to relieve the
requirement for the ESE for splicing of IgM M1-M2 by DNDRS
by simultaneously improving the polypyrimidine tract and
mutating the ESS. We generated the IgMPyq substrate, in
which the polypyrimidine tract was replaced with a consensus
U2AF
65 binding site (UUUUUUCCCUUUUUUUUUC, as in
[21]), and the IgMPyqDE substrate, in which the enhancer was
also deleted. To these substrates we added the PTB site I mutation,
to create IgMPyqPTB and IgMPyqDEPTB. IgMPyq and
IgMPyqPTB could both be spliced in S100 complementation
with either SF2/ASF or DNDRS (Figure 4, lanes 8 and 9, and
lanes 20 and 21), but IgMPyqDE, lacking an enhancer, could not
be spliced with either protein (lanes 11 and 12). Although trace
amounts of splicing were detectable for IgMPyqDEPTB in S100
complementation with either SF2/ASF or DNDRS (Figure 4, lanes
23 and 24), we were largely unable to relieve the requirement for
an ESE by simultaneously mutating the ESS and improving the
polypyrimidine tract. However, there are notable differences
between our experimental conditions and the manner in which the
analogous experiment was carried out by Graveley et al, most
important of which is that our experiment was an S100
complementation assay, rather than splicing in nuclear extract.
In addition, our assay utilized IgM M1-M2 with a mutation in the
PTB site I [45], rather than the IgM MS2 substrate [21], which
does not have the silencer because it lacks most of exon M2
downstream of the enhancer.
We conclude from these experiments that the ESE is required
for splicing of IgM M1-M2 in S100 complementation with either
SF2/ASF or DNDRS, suggesting that DNDRS, like SF2/ASF,
exerts at least some of its effects to activate splicing from the
position of the exonic splicing enhancer. Significantly, our data
also suggest that the RS domain is not required for enhancer-
dependent SR protein functions, at least in the context of IgM M1-
M2, as the levels of splicing of IgM M1-M2 and IgM-derivative
substrates with DNDRS were comparable to, or greater than,
those observed with SF2/ASF. An RS domain tethered to the ESE
position was found to be insufficient to activate splicing of an IgM
substrate in S100 complementation assays, and the addition of an
intact SR protein to the reaction is required for splicing to occur
under these conditions [27,45,59]. An N-terminally His-tagged
DRS protein was found to be unable to perform ESE-independent
SR protein function(s) in this context [27]; however, we
demonstrate using DNDRS as the sole source of SR protein in
our complementation assays that the RS domain is also not
required for this additional SR protein function(s) to support
splicing of IgM M1-M2.
DISCUSSION
Possible mechanisms of inhibition of splicing by the
N-terminus of SF2/ASF
Historically, SR protein RS domains were thought to be essential
for constitutive splicing, because a recombinant SR protein lacking
its RS domain was unable to complement S100 for splicing of
constitutive substrates. In retrospect, what these early experiments
may have been demonstrating was the importance of sequences
preceding RRM1 in influencing the ability of SR proteins to be
recruited to pre-mRNA. Initial experiments to test whether the RS
domain of SF2/ASF is required for splicing were carried out with
Figure 4. An exonic splicing enhancer is required for splicing of IgM M1-M2 with DNDRS. In vitro splicing of IgM M1-M2 and derivative pre-mRNAs
with mutations in the polypyrimidine tract, exonic splicing enhancer, and/or exonic splicing silencer: IgM M1-M2 (lanes 1-3), IgMDE (lanes 4–6),
IgMPyq (lanes 7–9), IgMPyqDE (lanes 10–12), IgMPTB (lanes 13–15), IgMDEPTB (lanes 16–18), IgMPyqPTB (lanes 19–21), and IgMPyqDE PTB (lanes
22–24, mRNA position indicated by asterisk); in S100 alone (lanes 1, 4, 7, 10, 13, 16, 19, and 22), and S100 complemented with 16 pmol of SF2/ASF
(lanes 2, 5, 8, 11, 14, 17, 20, and 23), or DNDRS (lanes 3, 6, 9, 12, 15, 18, 21, and 24). The splicing efficiency is indicated below each lane.
doi:10.1371/journal.pone.0000854.g004
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consistently showed that the RS domain of SF2/ASF was required
for constitutive splicing [40,41,62]. Subsequent experiments using
a version of DRS with no tag at the N-terminus unexpectedly
showed that the RS domain was dispensable for splicing of some
substrates [42]. We have not ruled out the possibility that deletion
of sequences from the N-terminus, including the N-terminal
extension to RRM1, increase the ability of DRS to bind to pre-
mRNA and promote splicing merely by increasing solubility of the
SR protein. Nonetheless, we now find that deletion of the majority
of the amino acids preceding RRM1 in the context of the DRS
protein permits splicing even of the IgM M1-M2 pre-mRNA,
a substrate previously classified as RS-domain-dependent, further
demonstrating that the RS domain is dispensable for constitutive
splicing in vitro.
RRMs can have N-terminal and C-terminal extensions
augmenting their core structure that are usually poorly ordered,
but in some cases adopt a secondary structure [46]. In cases in
which their functions have been documented, these N-terminal
and C-terminal extensions of RRMs modulate nucleic acid
binding by the core RRM. For some of these RRMs, the
extensions can fold over onto the RNA-binding surface of the core
domain to mask key residues involved in nucleic acid binding
[54,55,63]. Several SR proteins, including SF2/ASF, have N-
terminal extensions preceding their first RRM (Figure 2). The 20
available NMR structures of RRM1 of SF2/ASF [64] when
viewed collectively hint that the N-terminal extension is probably
flexible and can adopt many different conformations, such that
this region could sometimes occlude key RNA-binding residues on
the protein’s b-sheet. The observed flexibility of the N-terminal
extension could be due in part to an additional hydrophilic-tag
extension that was added for the purpose of improving solubility in
the structure determination.
Based on our data and the documented functions of other RRM
extensions, we propose that the most likely explanation for the
inhibitory effect of amino acids 2-11 of SF2/ASF on splicing is that
the N-terminal segment negatively affects RNA binding by
RRM1. In this model, the N-terminal domain may be inhibitory
by functioning as a damper upon RRM1 to interfere with its
binding to the RNA. Indeed, we have observed in UV crosslinking
assays that deletion of the N-terminal extension from DRS greatly
enhances apparent binding of the protein to IgM M1-M2 RNA
(Figure 3B). These quantitative differences in crosslinking probably
reflect differences in binding; although residues outside the b-sheet
could potentially crosslink also, the major sites of crosslinking likely
involve conserved aromatic residues in the RNP-1 and RNP-2
core submotifs at the center of the b-sheet, as has been shown for
the RRMs of hnRNP A1 [65]. Addition of an N-terminal tag to
DRS may exacerbate the inhibitory effect of the natural N-
terminus on RNA binding, accounting for the early observations
that His-tagged SF2/ASF lacking its RS domain was unable to
support constitutive splicing [40,41,62]. Curiously, the R8E
mutation, but not the V6A/I7A/R8A or R8A mutations,
abrogated the inhibitory effects of the N-terminus on the ability
of DRS to support splicing of IgM M1-M2 (Figure 1C). In
a scenario in which the N-terminal extension of RRM1 prevents
recruitment of DRS to pre-mRNA by blocking access to key RNA-
binding residues on the b-sheet, substitution of the conserved
arginine with an acidic residue, but not with an uncharged residue,
may be sufficient to interfere with potential intramolecular
interactions between the N-terminal extension preceding RRM1
and the RNA-binding surface of the protein.
We propose that in the context of the splicing reaction, the SF2/
ASF RS domain normally assists in overcoming the inhibitory
effect of the N-terminus, most probably by helping to recruit the
RRM(s) to the RNA. Thus, one possible reason for the previously
reported, apparent RS-domain-dependence of some substrates
could be that in the context of these pre-mRNAs, binding of
RRM1 of SF2/ASF is inhibited, due to unfavorable secondary
structure of the pre-mRNA or steric block by proteins bound
adjacent to the RRM1 target, or both; a hypophosphorylated RS
domain might therefore assist in initial recruitment of SF2/ASF to
its target, through its own charge-mediated contacts with adjacent
RNA sequences, bringing in the N-terminal RRM region so that it
can directly contact the RNA. In agreement with this hypothesis,
using a UV crosslinking assay, we observed little difference
between crosslinking of SF2/ASF and DNSF2/ASF to IgM M1-
M2 pre-mRNA, whereas the DRS protein bound less efficiently to
IgM M1-M2 than did either SF2/ASF or DNSF2/ASF; however,
when the N-terminal extension was deleted from DRS, its binding
to the pre-mRNA was greatly enhanced (Figure 3B).
Constitutive splicing without an SR protein RS
domain
Our finding that the RS domain is not required for constitutive
splicing of IgM M1-M2 seemingly contradicts prevailing models
about how SR proteins function to promote splicing. The previous
finding that the RS domain is dispensable for splicing of some
substrates but not for others [42] hinted that SR proteins may
activate splicing in a manner that does not always involve SR
protein RS-domain-mediated protein-protein interactions. How-
ever, because some substrates were found to require the RS
domain, RS-domain-mediated recruitment functions of SF2/ASF
could not be formally discounted, and were still hypothesized to
occur for RS-domain-dependent substrates. Splicing in the
absence of an SR protein RS domain suggests two possibilities
for how the domains of SR proteins function to promote pre-
mRNA splicing from the ESE position. First, the RS domain may
indeed be required in some contexts for recruitment functions of
SR proteins, and in contexts where the protein is active in the
absence of the RS domain, the DRS portion of the protein may
promote splicing by antagonizing the function of splicing silencers.
Second, the DRS portion of the protein may be sufficient to recruit
splicing factors to activate splicing. As the number of constitutive
substrates that can be spliced without an SR protein RS domain
continues to grow, it seems increasingly improbable that SR
proteins lacking their RS domains can only support splicing in
contexts where recruitment functions of SR proteins are dispens-
able. Instead, it appears more likely that protein-protein interac-
tions occurring through the RS domain of SR proteins are not
essential for recruitment of splicing factors, a finding that seems at
odds with current recruitment models for SR protein function.
The traditional recruitment models for SR protein function
assume that the ESE-bound RS domain of an SR protein interacts
with the RS domain of another splicing component, such as
U2AF
35 or U1-70K. Much support has been garnered for the SR
protein RS domain-mediated recruitment model, through experi-
ments that employed MS2-RS domain fusion proteins as splicing
activators [21,56,59]. However, if our DNDRS protein is
functioning to recruit other splicing components, it cannot be
doing so through RS-RS domain interactions. Although there is
evidence to suggest that SR proteins assist in the recruitment of
essential splicing factors, such as U2AF
35 or U1-70K, which
themselves have RS domains, it is not clear that this recruitment
requires the RS domains of both of the involved proteins. For
example, the RS domain of SF2/ASF is not required for
enhancement of U1 snRNP binding to alternative 59 splice sites
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RS-domain-containing protein U1-70K. Indeed, it is unlikely that
the SF2/ASF RS domain can function to recruit U1 snRNP
through interactions with U1-70K, as the isolated, unphosphory-
lated RS domain of SF2/ASF is not sufficient for interaction with
U1-70K [15]. It seems more probable that some portion of SF2/
ASF other than, or in addition to, the RS domain engages in
protein-protein interactions with U1-70K to recruit U1 snRNP,
considering that a GST-DRS fusion protein can engage in RNA-
independent protein-protein interactions with U1-70K [15]. Some
labs have reported that at least one of the RS domains of SF2/ASF
and U1-70K is required for interactions between these two
proteins [13,67], but these experiments did not demonstrate that
the RS domains of both proteins were required for their
interaction. The proposed recruitment function of SR proteins
for which the most experimental evidence has been assembled is
the model in which an ESE-bound SR protein engages via its RS
domain in protein-protein interactions with the RS domain of
U2AF
35 to aid in the recruitment of U2AF
65 to the polypyrimidine
tract [3,16]. However, several lines of evidence suggest that only
one of these two U2AF RS domains is required for efficient
splicing [68,69,70], and the RS domain of U2AF
35 is dispensable
for complementation of U2AF-depleted extract [44], leaving open
the possibility that the RS domain of U2AF
35 is likewise not
needed for interaction with an ESE-bound SR protein.
It has been demonstrated that an RS domain at the position of
the ESE, whether synthetic [29,42] or authentic [56], and whether
targeted there via an SR protein RRM [42], a heterologous RNA-
binding domain, such as the MS2 coat protein [56,57], or an
antisense oligonucleotide [29], can function to promote splicing,
whether this splicing activation occurs from the ESE through
influencing the recruitment of other splicing factors or by
promoting base-pairing of U snRNAs to pre-mRNA. From these
experiments we may conclude that one of the primary functions of
ESEs is to recruit an RS domain. However, an ESE is still required
for splicing of IgM M1-M2 with our DNDRS protein, which lacks
an RS domain. Clearly, recruitment of an RS domain by any
means to the position of the ESE can function to promote splicing,
yet in conjunction with the previous report of RS-domain-
independent splicing [42] our data strongly suggest that the SR
protein RS domain is not required at this position to activate
splicing. This apparent paradox can be resolved if we consider that
the function of an SR protein may not be to recruit other splicing
factors through its RS domain, but rather simply to recruit an RS
domain, whether its own or the RS domain of another splicing
factor. In an SR protein RS-domain-independent recruitment
model, the SR protein would interact with another splicing factor,
and this interaction must recruit at least one RS domain for
splicing to be activated. An SR protein lacking its RS domain
could activate splicing by interacting, for example, with U2AF
35,
which itself has an RS domain, or with U1-70K, which also has its
own RS domain. Such a mechanism would be analogous to the
situation described for U2AF
65 and U2AF
35, which interact with
each other and both have RS domains, but only one of the two RS
domains is required for splicing to occur [68,69,70]. Indeed, the
requirements for the identity of the RS domain recruited to the ESE
position to function as a splicing activator are far from stringent, as
the RS domain from any SR protein [56,59,71], from U2AF
65
[27,57,71], U2AF
35 [57,71], U1-70K [71], or even a synthetic RS
domain [29,57,71] are all sufficient for this purpose.
Our data strongly suggest that SR protein RS-domain-mediated
protein-protein interactions are not required for SR proteins to
promote recruitment of other splicing factors. Alternatively, the
DRS portion of SF2/ASF, which consists of two RRMs separated
by a glycine-rich linker, may itself be engaging in protein-protein
interactions with other proteins of the spliceosome. There are
precedents for this possibility, as several other essential splicing
factors have already been demonstrated to interact with each other
through protein-protein interactions involving their RRMs
[72,73,74]. Using the DNDRS protein, the roles of portions of
SR proteins other than their RS domains in promoting splicing
can be explored in the future.
MATERIALS AND METHODS
Cloning Procedures
The pTT3 vector [75] was employed for expression of C-
terminally His-tagged SR proteins in 293-EBNA1 cells; plasmids
pTT3-SF2His and pTT3-SF2DRSCHis code for amino acids 1-
248 and 1-196 of SF2/ASF, respectively. Plasmids for expression
of N-terminus mutant proteins were created by deletion or
mutation of sequences in the pTT3-SF2His and pTT3-
SF2DRSCHis plasmids, either as described in the Stratagene
Quikchange Site-Directed Mutagenesis Kit manufacturer’s pro-
tocol or using a site-directed mutagenesis strategy with a common
reverse primer and mutagenic forward primers that overlap at
their 59 ends with the reverse primer. The protein-coding regions
for all protein expression plasmids were verified by sequencing.
Plasmids containing transcription templates for IgM M1-M2
splicing substrates with mutations or deletions in the polypyr-
imidine tract, exonic splicing enhancer, and/or exonic splicing
silencer were generated by either overlap-extension PCR or site-
directed mutagenesis. Overlap-extension PCR [76] was carried
out using Pfu Turbo polymerase (Stratagene), using outside
primers to pSP65-mM1-M2 [58] upstream of the SP6 transcription
start site and downstream of the XbaI site used for the
transcription runoffs. Overlapping PCR products were cloned
into the pCR-Blunt vector (Invitrogen). All transcription templates
were verified by sequencing. IgMPyq was generated by overlap-
extension PCR with pSP65-mM1-M2 as a template, using inside
primers to introduce the mutant polypyrimidine tract
59UUUUUUCCCUUUUUUUUUC39 [21] in place of the
wild-type polypyrimidine tract 59ACACUGUCUCUGUCAC-
CUG39. IgMDE was generated by overlap-extension PCR with
pSP65-mM1-M2 as a template, using inside primers to delete the
23-nt enhancer 59GAAGGACAGCAGAGACCAAGA39 in exon
M2 [23]. IgMPTB was generated by site-directed mutagenesis of
the pSP65-mM1-M2 plasmid to introduce the mutant PTB site I
59ACAUACGACAU39 [45] in place of the wild-type site
59UCUUACGUCUU39. IgMPyqDE was generated by overlap-
extension PCR with pCR-Blunt-IgMDE as a template, using
inside primers as described above to introduce the mutant poly-
pyrimidine tract in place of the wild-type polypyrimidine tract.
IgMDEPTB, IgMPyqPTB, and IgMPyqDEPTB were generated
by site-directed mutagenesis of the pCR-Blunt-IgMDE, pCR-
Blunt-IgMPyq and pCR-Blunt-IgMPyqDE plasmids, respective-
ly to introduce the mutant PTB site I as described above.
Protein Expression and Purification
SF2/ASF, DRS, and N-terminus mutant proteins were expressed
as C-terminally His-tagged fusion proteins from the pTT3-SF2His
and pTT3-SF2DRSCHis plasmids or derivatives of these plasmids,
respectively, after transfection with polyethylenimine (PEI) into
293-EBNA1 cells [75]. 293-EBNA1 cells (Invitrogen) were
maintained in suspension culture at a density of 2.5610
5 cells/
mL in MEM Joklik’s suspension modification medium with L-
glutamine (US Biological) supplemented with 5% calf serum
(Gibco) and penicillin/streptomycin. For transfection, 1L of cells at
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5 cells/mL were allowed to grow for 24 hours and then
transfected by the addition of 1 mg of plasmid, 50 mL of culture
medium, and 2 mg of PEI linear MW=25,000 (Polysciences) to
the suspension cell culture.
After transfection, cultures were grown for three days to allow
for protein expression. Pelleted cells were washed with PBS and
resuspended in a lysis buffer consisting of 1 M NaCl, 0.1% v/v
Triton X-100, 20 mM b-mercaptoethanol, 50 mM TRIS-HCl pH
8.0, 10 mM imidazole, supplemented with the EDTA-free
Complete Mini protease inhibitor tablet (Roche) prior to
sonication. The sonicate was centrifuged at 15,000 rpm, and a
0-30% saturated ammonium sulfate cut was carried out on the
supernatant, followed by another 15,000 rpm centrifugation. The
second supernatant was diluted with an equal volume of lysis
buffer without salt and then incubated at 4uC with Ni-NTA
agarose beads (Qiagen) in batch. Beads were washed on a column
with 50 volumes of lysis buffer without Triton X-100, and proteins
were eluted in lysis buffer with 1 M NaCl and 300 mM imidazole
and without Triton X-100. After elution from the Ni-NTA agarose
column, fractions containing SR protein were combined. If the
protein concentration was at least 3 mg/mL for the pooled peak
fractions, proteins were directly dialyzed twice against Buffer D,
consisting of 20 mM HEPES-KOH pH 8.0, 0.2 mM EDTA, 20%
(v/v) glycerol, 0.4 M KCl, 1 mM DTT, and 0.5 mM PMSF. If the
protein concentration was less than 3 mg/mL after combining
peak fractions, proteins were denatured by dialyzing into Buffer D
with 6 M urea at 0.1 M KCl, and then concentrated at 4uCt o
approximately 3 mg/mL using a Centricon-10 concentration
device (Millipore Corporation). Concentrated proteins were
refolded by sequential dialyses in Buffer D containing 3 M urea
and 0.4 M KCl, 1.5 M urea and 0.4 M KCl, 0.75 M urea and
0.4 M KCl, and finally into Buffer D.
In Vitro Splicing Assays
Splicing substrates were transcribed from plasmid templates
linearized with XbaI using SP6 RNA polymerase (Promega),
essentially as described in [77], except that G(59)ppp(59)G cap
analog (NEB) was used instead of
7mGpppG cap analog. All
transcripts were gel-purified. HeLa cell cytoplasmic (S100) extracts
were prepared as described in [78]. In vitro splicing assays were
carried out essentially as described in [79]. Briefly, 10-mL reactions
containing 0.5 mM ATP, 20 mM creatine phosphate, 20 mM
HEPES-KOH pH 7.3, 2.6 % (w/v) polyvinyl alcohol, 1.6 mM
MgCl2, 20 fmol a
32P-UTP labeled splicing substrate, 30% (v/v)
S100, and 16 pmol SR protein were set up on ice. For S100
complementation reactions with SR proteins in 0.4 M KCl Buffer
D, the final salt concentration for the splicing reaction was
adjusted to 60 mM using Buffer D without salt. Splicing reactions
were incubated at 30uC, followed by phenol extraction and
ethanol precipitation. RNA was resuspended in formamide/
bromophenol blue/xylene cyanol FF loading dye, and separated
in a 5.5% acrylamide/8.3 M urea gel. Bands were visualized by
autoradiography using X-OMAT film (Kodak) or by exposure to
a FUJI PhosphorImager screen and analysis with an Image
Reader FLA-5100 (FujiFilm Medical Systems, Stamford, Con-
necticut, United States). Percent splicing was calculated as
[mRNA/(mRNA+pre-mRNA)]6100.
UV Crosslinking
Protein binding was performed in 20-mL reactions containing
32 pmol of SR protein or BSA, 80 fmol of uncapped IgM M1-M2
RNA labeled with all four NTPs, in reaction buffer conditions with
final concentrations of 1.6 mM MgCl2, 20 mM HEPES-KOH pH
7.3, 0.5 mM ATP, 20 mM creatine phosphate, and 60 mM KCl.
RNA was denatured prior to incubation with protein; RNA mixes
containing 80 fmol of labeled IgM M1-M2, MgCl2, and water
were assembled at 4uC, heated at 95uC for five minutes, and then
returned to ice. 32 pmol of BSA or SR protein in Buffer D was
then added to each reaction along with the other splicing buffer
components, and reactions were incubated at 30uC for 30 min-
utes. Binding reactions were spotted onto parafilm and placed on
ice prior to UV crosslinking at 0.864 J/cm
2 in a Spectrolinker XL-
1000 UV Crosslinker (Spectronics Corporation). Reactions were
returned to Eppendorf tubes, and 3 mL of 27 mg/mL RNAse A
and 2 mL of 1000 U/mL RNAse T1 (Roche) were added prior to
incubation at 37uC for 15 minutes. Proteins and RNA were
separated by 12% SDS-PAGE prior to visualization by autoradi-
ography and phosphorimaging.
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